Crizotinib CAS 877399-52-5 Assay ≥99.0% API High Quality Factory
Shanghai Ruifu Chemical Co., Ltd. shine babban masana'anta na Crizotinib (CAS: 877399-52-5) tare da babban inganci.Ruifu Chemical na iya samar da isar da saƙo na duniya, farashi mai gasa, kyakkyawan sabis, ƙanana da adadi mai yawa akwai.Sayi Crizotinib,Please contact: alvin@ruifuchem.com
| Sunan Sinadari | Crizotinib |
| Makamantu | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1- (2,6-Dichloro-3-Fluoro-phenyl) -ethoxy] -5- (1-Piperidin-4-yl-1H-pyrazol-4-yl) -pyridin-2-ylamine;(R) -3-[1- (2,6-Dichloro-3-Fluorophenyl)ethoxy]-5- (1-Piperidin-4-yl-1H- pyrazol-4-yl) pyridin-2-ylamine |
| Lambar CAS | 877399-52-5 |
| Matsayin Hannun jari | A Hannun jari, Ma'aunin Samfuran Har zuwa Daruruwan Kilogram |
| Tsarin kwayoyin halitta | Saukewa: C21H22Cl2FN5O |
| Nauyin Kwayoyin Halitta | 450.34 |
| Matsayin narkewa | 192 ℃ |
| Yawan yawa | 1.47± 0.10 g/cm3 |
| Ajiya Zazzabi | Yanayin Daki |
| Asalin | Shanghai, China |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai |
| Bayyanar | Fari zuwa Kashe-Farin Foda |
| Ganewa | By IR, HPLC |
| Bayyanar Magani | Yi daidai da Standard |
| Asara akan bushewa | ≤1.00% |
| Ragowa akan Ignition | ≤0.50% |
| Abubuwan da ke da alaƙa | (da HPLC) |
| Tsaftace Guda Daya | ≤0.50% |
| Jimlar ƙazanta | ≤1.00% |
| Karfe masu nauyi | ≤20ppm |
| Assay | ≥99.0% |
| Ragowar Magani | Haɗu da ƙayyadaddun bayanai |
| Rayuwar Rayuwa | Watanni 24 |
| Matsayin Gwaji | Matsayin Kasuwanci |
Kunshin:Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye akwati sosai kuma a adana a wuri mai sanyi, bushe (2 ~ 8 ℃) da ma'ajin da ke da isasshen iska daga abubuwan da ba su dace ba.Kare daga haske da danshi.
Jirgin ruwa:Isar da shi zuwa duniya ta iska, ta FedEx / DHL Express.Bayar da isarwa cikin sauri kuma abin dogaro.
Bayanin Tsaro 24/25 - Guji hulɗa da fata da idanu.
ID na UN UN 3077 9 / PGIII
WGK Jamus 3
Lambar 2933990099
Ajin Hazari MAI GIRMA
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), mai ƙarfi ne kuma mai zaɓin ATP gasa ƙananan ƙwayoyin ƙwayoyin cuta na ALK da c-Met.A watan Agustan 2011, FDA ta Amurka ta amince da Crizotinib don maganin anaplastic lymphoma kinase (ALK) wanda ya sake tsara ciwon huhu na ƙananan ƙwayar cuta (NSCLC).Crizotinib ne mai dual ATP m inhibitor na tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) da ALK (cellular IC50 = 20 nM), dukansu biyu suna da muhimmiyar manufa don ciwon daji chemotherapy.Lokacin da aka gwada crizotinib don zaɓi da sauran kinases an gano cewa yana da enzyme IC50's a cikin 100-ninka na c-MET don 13 na 120 kinases da aka gwada.A cikin gwaje-gwajen salula, an gano crizotinib don hana RON (mai karɓar ra'ayin nantais) kinase tare da taga zaɓi mai ninki 10 akan c-MET.
Crizotinib (PF-02341066) Crizotinib shine mai karfin c-Met da ALK inhibitor, ƙimar IC50 a cikin gwajin tantanin halitta sune 11 nM da 24 nM, bi da bi.Hakanan shine mai hanawa mai ƙarfi na ROS1 tare da ƙimar Ki ƙasa da 0.025 nM.Crizotinib na iya haifar da autophagy a cikin nau'o'in kwayoyin cutar kansa ta huhu ta hanyar hana hanyar STAT3.
Crizotinib shine mai hanawa mai ƙarfi da zaɓaɓɓen dual inhibitor na mesenchymal-epithelial transition factor (c-MET) kinase da anaplastic lymphoma kinase (ALK).Crizotinib shine yuwuwar wakili na antitumor.A watan Agustan 2011, FDA ta Amurka ta amince da crizotinib don maganin anaplastic lymphoma kinase (ALK) ya sake shirya kansar huhu mara ƙananan-cell (NSCLC).
Crizotinib (Xalkori (R), Pfizer), wanda aka amince da shi a cikin 2011, shine farkon wanda aka yarda da mai hanawa wanda ke niyya anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) na tyrosine kinase insulin receptor class da MET proto-oncogene-encoded kinase na hepatocyte girma factor receptor (HGFR) aji wasu kinases ne da crizotinib.Lokacin da aka amince da shi a 2011, crizotinib shine farkon farko. miyagun ƙwayoyi na musamman da aka yi niyya ga marasa lafiyar NSCLC.Duk da haka, juriya ga crizotinib yawanci ana lura da shi a cikin kimanin watanni 8 bayan aikace-aikacen farko kuma fiye da rabin marasa lafiya na crizotinib sun sami sakamako masu illa na gastrointestinal.A cikin 2016, an kuma yarda da Crizotinib don ROS1-tabbatacce NSCLC ta FDA.
Crizotinib (Xalkori) shine mai karɓar mai karɓar tyrosine kinase mai hanawa na baka wanda aka nuna don kula da marasa lafiya masu ci gaba ko ciwon daji marasa ƙananan ƙwayoyin cuta (NSCLC).Illolin da aka saba da su tare da amfani da Xalkori sun haɗa da kamuwa da cuta na numfashi na sama, tashin zuciya, amai, ciwon ciki, rage cin abinci, rashin barci, tashin hankali, gajiyar ji, gudawa, maƙarƙashiya, kurji ko ƙaiƙayi, alamun sanyi (hanci, atishawa, ciwon makogwaro), numbness ko tingling, ko kumburi a hannunka ko ƙafafu.
